The 2nd Gene Therapy Immunogenicity Summit is the industry's definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate.
In the context of ever-increasing gene therapy clinical activity and uncertainty around immunogenicity challenges, the Gene Therapy Immunogenicity Summit will unite large pharma and innovative biotechs to ensure that you're up to speed on the latest approaches to predict, measure and overcome every immunogenicity challenge you encounter.
Focused specifically on examining gene therapy immunogenicity, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune-modulatory approaches could enable re-dosing and learn the reality of regulatory expectations around immunological assays.
Incorporating insights from leading immunological, bioanalytical and translational experts, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing approaches to address immunogenicity.
Conference Only Ticket (First Release): USD 1599.0,
Conference Only Ticket (Second Release): USD 1699.0,
Conference Only Ticket (Third Release): USD 1899.0,
Conference Only Ticket (Fourth Release): USD 1999.0,
Conference Only Ticket (Final Price): USD 2099.0
Speakers: Andrew Byrnes, Head Gene Transfer and Immunogenicity Branch, FDA, Klaudia Kuranda, Immunology Lead, Spark Therapeutics, David Markusic, Research Professor, IUPUI, Cathryn Clary, Acting Chief Medical Officer, Bridge Bio, Susan Ward, Founder and Executive Director, cTAP - Duchenne, Federico Mingozzi, Chief Scientific Officer, Spark Therapeutics, John Kamerud, Bioanalytical Lead, Pfizer, Boris Gorovitz, Vice President, In vitro Pharmacology, Biomarker Discovery and Bioanalysis at Development Sciences, Sana Biotechnology, Roberto Calcedo, Vice President, Preclinical and Immunology, Affinia Therapeutics, MiJeong (MJ) Kim, Associate Director of Immunology, Homology Medicines, Maria Lobikin, Associate Director, CMC Regulatory Affairs, Homology Medicines, Kei Kishimoto, Chief Scientific Officer, Selecta Bioscience, Roland Herzog,Riley Children's Foundation Professor of Immunology, Indiana University, Pierre Burguiere, Independent Consultant (Formerly Director - Translational Research), GenSight Biologics, Genevieve Laforet, Vice President, Clinical Development, Aspa Therapeutics, Genine Winslow, Chief Scientific Officer, Chameleon Bioscience, Jose Trevejo, Chief Development Officer, Rocket Pharmaceuticals, Liching Cao, Director, Bioanalytical Operations, Sangamo Therapeutics, Vibha Jawa, Executive Director, Bristol Myers Squibb, Guangping Gao, Professor and Director, UMass Medical School, Zuben Sauna, Principal Investigator, US FDA, Mark Milton, Opthalmology Area Head, Novartis, Helene Haegel, Principal Scientist Immunosafety, Roche, Giuseppe Gonzitti, Group Leader, Genethon, Stephen DeWall, Biopharmaceutical Immunogenicity Leader, Spark Therapeutics
Time: 08:00 - 17:30